USFDA issues 3 observations for Alkem Labs Mandva facility

Published On 2023-12-02 06:02 GMT   |   Update On 2023-12-02 12:25 GMT

Mumbai: Through a recent BSE filing, Alkem Labs has informed that the Company has received Form 483 with three observations from the United States Food and Drug Administration (USFDA) at the end of the inspection conducted at the Company’s API manufacturing facility located at Mandva. There is no data integrity observation.An FDA Form 483 is issued to firm management at the conclusion of...

Login or Register to read the full article

Mumbai: Through a recent BSE filing, Alkem Labs has informed that the Company has received Form 483 with three observations from the United States Food and Drug Administration (USFDA) at the end of the inspection conducted at the Company’s API manufacturing facility located at Mandva. There is no data integrity observation.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. 

USFDA inspected the facility from 27th November, 2023 to 01st December, 2023.

"This Inspection is part of the routine business operations and the Company shall submit to US FDA within the stipulated timeline, a detailed response to close out the said observations," Alkem said.

Read also: Anti-infective for severe fungal infections: Alkem Labs joins hands with Biosergen for development of BSG005

Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, Ophthalmology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.

Read also: Alkem Laboratories gets CDSCO panel nod to manufacture, market Dapagliflozin Propanediol Monohydrate, Linagliptin FDC in lower strength

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News